R&D News | pharmaphorum

News

Roche delivers its data reveal for adjuvant giredestrant

Roche reveals the data that has it excited about giredestrant in early-stage breast cancer, but how might it be positioned versus CDK4/6 inhibitors?

News

Measuring tape overlain on a dark yellow background

Pfizer's $2bn+ obesity bet, and other weight-loss news

Pfizer licenses another GLP-1 agonist, from YaoPharma, plus clinical updates from Zealand, Structure, Ascletis, Wave, and Boehringer Ingelheim.

News

FDA set to raise bar for clinical trials of CAR-T therapies

The FDA could make it harder for developers of CAR-T therapies to bring them to market by requiring full randomised controlled trials.

News

Lab-in-a-loop specialist Relation attracts Novartis alliance

UK-based AI and multi-omics company Relation Therapeutics will seek out targets for allergic diseases on behalf of Novartis in a $1.7bn-plus alliance.

News

FDA backs first AI tool for use in trials, targeting MASH

The FDA has qualified the first AI-based tool that can be used in clinical trials involving patients with MASH to help measure disease activity.

News

ASH: Jaypirca matches Imbruvica in first-line CLL trial

Eli Lilly has revealed the data it hopes will take BTK inhibitor Jaypirca into frontline use for chronic lymphocytic leukaemia.

Roche delivers its data reveal for adjuvant giredestrant

Pfizer's $2bn+ obesity bet, and other weight-loss news

FDA set to raise bar for clinical trials of CAR-T therapies

Lab-in-a-loop specialist Relation attracts Novartis alliance

FDA backs first AI tool for use in trials, targeting MASH

ASH: Jaypirca matches Imbruvica in first-line CLL trial

Ambrosia's sweet $100m round, and other biofinancings

Using AI-driven synthetic personas to take your insights fur...

News

Editor's Picks